Want to see QURE full AI Analyst Report?
QURE Stock Chart & Stats
$51.05
$0.25(0.64%)
At close: 4:00 PM EDT
$51.05
$0.25(0.64%)
Day’s Range― - ―
52-Week Range$8.73 - $71.50
Previous CloseN/A
Volume30.69K
Average Volume (3M)2.87M
Market Cap
$1.58B
Enterprise Value$2.79B
Total Cash (Recent Filing)$810.34M
Total Debt (Recent Filing)$62.83M
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Nov 10, 2026EPS Estimate
-0.92Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.04
Shares Outstanding69,366,410
10 Day Avg. Volume1,997,663
30 Day Avg. Volume2,871,027
Financial Highlights & Ratios
PEG Ratio0.23
Price to Book (P/B)6.92
Price to Sales (P/S)85.48
P/FCF Ratio-7.73
Enterprise Value/Market Cap1.77
Enterprise Value/Revenue149.58
Enterprise Value/Gross Profit656.41
Enterprise Value/Ebitda-15.43
Forecast
1Y Price Target
$53.57Price Target Upside4.94% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering10
EPS Forecast (FY)-3.88
Revenue Forecast (FY)$23.45M
Bulls Say, Bears Say
Bulls Say
AMT-130 Regulatory And Clinical ProgressAMT-130 has advanced from clinical development toward potential commercialization, supported by longer-term data and regulatory submissions in major markets. If reviews validate the evidence, uniQure could establish a leading position in Huntington’s disease and create a foundation for broader central nervous system gene-therapy growth.
Extended Cash RunwayA substantial cash position and stated runway into 2030 reduce near-term financing pressure while uniQure funds confirmatory studies, regulatory work, and potential commercialization. This provides strategic flexibility to pursue important programs without relying immediately on unfavorable capital raising or sharply reducing development activity.
Diversified Gene-therapy PipelineEarly clinical signals across epilepsy and Fabry disease extend the opportunity beyond AMT-130 and demonstrate that uniQure’s AAV and gene-therapy capabilities are being applied across multiple serious disorders. Additional successful development could diversify future milestones, royalties, and product opportunities.
Bears Say
Persistent Losses And Cash BurnThe company remains far from self-funding, with very small revenue relative to its expense base and substantial recurring operating losses. Continued cash consumption increases dependence on future financing, partnerships, or successful commercialization, while weak profitability limits resilience if clinical or regulatory timelines extend.
AMT-191 Dose-limiting Liver ToxicityThe AMT-191 dosing pause creates a meaningful development risk for a program intended to broaden the pipeline beyond AMT-130. Additional monitoring, possible protocol changes, and delayed higher-dose data could slow regulatory progress, increase development costs, and reduce confidence in the program’s therapeutic window.
Confirmatory-trial Execution BurdenAMT-130’s accelerated pathway still requires rapid global execution of a randomized confirmatory study, adding operational and financial demands near a potential launch. Failure to align, initiate, or enroll the trial quickly could delay approval, increase spending, or weaken the durability of the commercialization opportunity.
uniQure News
QURE FAQ
What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $8.73 and its highest was $71.50 in the past 12 months.
What is uniQure N.V.’s market cap?
uniQure N.V.’s market cap is $1.58B.
When is uniQure N.V.’s upcoming earnings report date?
uniQure N.V.’s upcoming earnings report date is Nov 10, 2026 which is in 18 days.
How were uniQure N.V.’s earnings last quarter?
uniQure N.V. released its earnings results on Jul 29, 2026. The company reported -$1.22 earnings per share for the quarter, missing the consensus estimate of -$0.822 by -$0.398.
Is uniQure N.V. overvalued?
According to Wall Street analysts uniQure N.V.’s price is currently Undervalued.
Does uniQure N.V. pay dividends?
uniQure N.V. does not currently pay dividends.
What is uniQure N.V.’s EPS estimate?
uniQure N.V.’s EPS estimate is -0.92.
How many shares outstanding does uniQure N.V. have?
uniQure N.V. has 69,366,410 shares outstanding.
What happened to uniQure N.V.’s price movement after its last earnings report?
uniQure N.V. reported an EPS of -$1.22 in its last earnings report, missing expectations of -$0.822. Following the earnings report the stock price went up 9.302%.
Which hedge fund is a major shareholder of uniQure N.V.?
Currently, no hedge funds are holding shares in QURE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
uniQure Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$53.57 (4.94% Upside)
$53.57 (4.94% Upside)
Blogger Sentiment
Neutral
QURE Sentiment 56%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 764.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-64.02%
12-Months-Change
Fundamentals
Return on Equity
-111.96%
Trailing 12-Months
Asset Growth
68.43%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
uniQure N.V.
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
QURE Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed strong positive momentum: regulatory progress (FDA alignment on using 3-year data as the basis for an accelerated BLA), an on-track BLA/MAA submission timeline, upcoming 4-year AMT-130 data, encouraging early efficacy and biological signals in AMT-260 and AMT-191, and a materially strengthened balance sheet with ~$810M cash supporting operations into 2030. Notable challenges include a pause in higher-dose AMT-191 dosing after Grade 3 LFTs (dose-limiting toxicity), mixed early efficacy in the AMT-260 low-dose cohort, increased SG&A to fund commercialization (near-term burn), and the operational/regulatory requirement to have the confirmatory trial well underway at the time of any accelerated approval. Taken together, the positives (regulatory clarity, data momentum, cash runway, early signals) outweigh the manageable clinical and execution risks identified.View all QURE earnings summariesQURE Stock 12 Month Forecast
Average Price Target
$53.57
▲(4.94% Upside)
Technical Analysis
Ownership Overview
2.00% Insiders
12.11% Mutual Funds
3.24% Other Institutional Investors
74.76% Public Companies and
Individual Investors